The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes
{{output}}
Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel pharmacological agent for diabetes and heart failure, may influence oncologic outcomes. Their role in advanced lung cancer patients with diabetes is unclear. ... ...
